Mirador Therapeutics, Inc.

Mirador is a next-generation precision medicine company focused on immunology and inflammation. The company’s Mirador360 TM precision development engine leverages the latest advances in human genetics and cutting-edge data science to rapidly advance new precision medicines for patients living with chronic immune-mediated inflammatory and fibrotic diseases. Launched in 2024, Mirador has raised over $400 million from leading life sciences investors and is based in San Diego, CA. For more information, please visit us at www.miradortx.com.

Our Chairman and CEO, Mark McKenna, was recently featured on the BioWorld Insider Podcast. In the episode, he delved into key insights about our mission at Mirador, discussing our innovative work in #precisionmedicine for inflammation and immunology (I&I) and touched upon macro industry trends shaping the future of healthcare.
3115 Merryfield Row, Suite 210
San Diego, CA 92121
  • Featured Employer
OUR VALUES

Mirador’s commitment to values of trust, ambition, collaboration, integrity, and excellence shapes our culture of teamwork, innovation, and relentless pursuit of developing transformative precision therapies for patients with immune-mediated diseases.

We trust each other, believing that we all have best intentions and are delivering our part of the collective vision to improve the lives of patients with immune-mediated diseases.

We hold each other accountable, trusting that we have each other’s backs.

We trust in the process and feel empowered to address challenges knowing they are part of how we win.

We think creatively, experiment fearlessly, and develop groundbreaking ideas that benefit our patients.

Our ambition fuels our moonshot thinking and relentless pursuit of our goals.

We are empowered to challenge the status quo and seek new solutions to make what seems impossible a reality.

We show up every day knowing that every team member brings unique value and perspective to our shared vision.

We know that our team output is stronger than the sum of our individual capabilities.

We encourage active listening, open-mindedness, and constructive feedback across all levels of the organization.

We support each other to make the right decisions and do the right thing.

We have a commitment to ethical conduct in all aspects of our business.

Our truth is driven by science and data, which we follow no matter where it leads.

We expect excellence in all we do.

We leverage diverse skills and perspectives to achieve excellence in our shared goals.

Individual excellence is a given; team excellence is our competitive advantage.

OUR VISION

Improve the lives of people with immune-mediated diseases through innovative precision medicine.

OUR MISSION

Develop transformational precision therapies for immune-mediated diseases by leveraging cutting-edge biology, multi-modal data, and advanced analytics.

NEWS
The J.P. Morgan Healthcare Conference started off with a flurry of deals that reinvigorated excitement across the biopharma industry. Johnson & Johnson moved to acquire Intra-Cellular Therapies for $14.6 billion, breaking a dealmaking barrier that kept Big Pharma’s 2024 biotech buyouts to under $5 billion.
From ADCs and radiopharmaceuticals to cell and gene therapies, eager young startups are betting on advances in biopharma’s most competitive therapeutic spaces—and attracting dollars from Big Pharma.
BioSpace has named 50 biopharma companies to its 2025 Best Places to Work list, including Moderna and Sutro Biopharma, whose executives share what makes their organizations special.
Looking for a biotech job in San Diego? Check out these seven top companies hiring life sciences professionals like you.
Looking for a biopharma job? Check out the BioSpace list of 11 top companies hiring life sciences professionals like you.
Mirador Therapeutics emerged from stealth Thursday with financing from ARCH Venture Partners and Sanofi, among others, to provide precision medicines for inflammatory and fibrotic diseases.
JOBS
IN THE PRESS